Key Takeaways
- The European Medicines Agency has issued a draft qualification opinion recommending the use of an AI-based pathology tool in clinical trials of drugs for metabolic dysfunction-associated steatohepatitis (MASH).
The European Medicines Agency is seeking feedback on the use of an artificial intelligence (AI)-based pathology tool that could provide...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?